Polfa hopes to inject new life into insulin market

"We will begin introducing the product to the market with the fourth phase of clinical research on 1,300 people. This phase allows us to prove the quality of the product," said Dariusz Sobczak, president of Polfa Tarchomin. In a few days the firm's insulin will be supplied to hospitals in seven voivodships, while in the second stage it will be delivered to six more regions. Polfa plans submitting its product to the list of refunded drugs. "Our price will be very attractive, but it will not be below the level set by Bioton," said Sobczak. The company is not intending to develop solely on the domestic market, "We have already commenced talks concerning the sales of the drug on foreign markets. For the time being I cannot reveal, which markets interest us most," said Sobczak. (Puls Biznesu, pp. 1, 6) M.M.